beyond spring pharmaceuticals stock

Workforce which is expected to. The stock recently traded at 2711 compared with its Tuesday close at 963.

Best Biotech Stocks To Watch In 2021 4 To Know Nasdaq

Ad Our Strong Track Record Has Enabled Us To Become A Leader In Rare Disease.

. Shares of the company were trading at their highest level since May 2018. BYSI stock quote history news and other vital information to help you with your stock trading and investing. We Are Well Positioned to Deliver Sustainable Top-Tier Growth Enhanced Shareholder Value.

We Are Well Positioned to Deliver Sustainable Top-Tier Growth Enhanced Shareholder Value. The stock was up 188 at 2774 as of 132 pm. Why Are BeyondSprings Shares Plunging Today.

BeyondSpring is a global clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from. Find real-time BYSI - Beyondspring Inc stock quotes company profile news and forecasts from CNN Business. BeyondSpring has a twelve month low of 113 and a twelve month high of 3300.

Intraday data delayed at least 15 minutes or per exchange. BeyondSpring NASDAQBYSI Get Rating last posted its quarterly earnings results. The stocks 50 day moving average is 171 and its.

New target price is 462 above last closing price of US243. Real time BeyondSpring Inc. On average they predict BeyondSprings share price to reach 3000 in the next twelve months.

Real-time last sale data for US. 1 day agoShares of BYSI opened at 177 on Friday. 20 2021 0222 PM.

They possess deep scientific clinical. Get Beyondspring Inc BYSINASDAQ real-time stock quotes news price and financial information from CNBC. All quotes are in local exchange time.

The Closing Price Days High Days Low and Days Volume have been adjusted to account for any stock splits. It had slid 27 in the six months through Tuesday. BeyondSpring NASDAQBYSI Get Rating last announced its earnings results.

The company on Wednesday said plinabulin. Ad Our Strong Track Record Has Enabled Us To Become A Leader In Rare Disease. Headquartered in New York City we are committed to raising the standard of care for cancer patients with first-in-class treatments that improve lives and clinical outcomes for.

In China we own a 5797 interest in our. The pharmaceutical company focused on the development of cancer therapeutics said on Tuesday it is implementing a 35 reduction in its US. BeyondSpring Pharmaceuticals holds the No.

The company showed -6 earnings growth last quarter while sales growth came in at 0. Amgen IncAmgen is a leader in biotechnology-based human therapeutics with historical expertise in renal disease and cancer supportive-care productsFlagship drugs. Find the latest BeyondSpring Inc.

The firm has a market capitalization of 6890 million a PE ratio of -108 and a beta of 121. 129 rank among its peers in the Medical. Their forecasts range from 500 to 6500.

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulins Fast Onset Mechanism of Action in the. Price target increased to US1367. Our management team is made up of a strong and diverse group whose specialties range from early-phase development to global clinical development.

BYSI stock price quote stock graph news analysis. Up from US1175 the current price target is an average from 4 analysts. BYSI stock are taking off on Wednesday following an important update regarding the firms lung cancer treatment.

1 We own global rights to plinabulin in all countries except China. 1 day agoThe stock has a market capitalization of 6891 million a PE ratio of -108 and a beta of 121. Is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies.

Shares of BeyondSpring NASDAQ. Stock quotes reflect trades reported through Nasdaq only. Shares of BeyondSpring BYSI 985 soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung.

In other cancer-drug news Infinity.

Eurobiotech Report Alzheimer S Gene Therapy Ipos Innate Pharma And A 160 Stock Surge Fierce Biotech